Phase II clinical trial of sorafenib plus local chemotherapy in the treatment of metastatic renal cell carcinoma with pleural effusion

National Medical Journal of China

Volumn 92, Issue 42, 2012, Pages 2998-3000

  Yang, Shao Yu ^a   Cui, Chuan Liang ^b   Chi, Zhi Hong ^b   Si, Lu ^b   Sheng, Xi Nan ^b   Mao, Li Li ^b   Lian, Bin ^b   Guo, Jun ^b  

^a HANGZHOU FIRST PEOPLE'S HOSPITAL   (China)

^b PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

Carcinoma, renal cell; Drug therapy; Pleural effusion; Sorafenib

Indexed keywords

CISPLATIN; SORAFENIB;

ABNORMAL LABORATORY RESULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; HUMAN; INCIDENCE; KIDNEY CARCINOMA; METASTASIS; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; THORAX PAIN; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NIACINAMIDE; PHENYLUREA COMPOUNDS; PLEURAL EFFUSION; TREATMENT OUTCOME;

EID: 84872255427     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0376-2491.2012.42.013     Document Type: Article

References (7)

1. Karumanchi S A, Merchan J, Sukhatme V P. Renal cancer: molecular mechanisms and newer therapeutic options Curr Opin Nephrol Hypertens. 2002, 11:37-42.
2. 1995, 7:50-52.
3. 2009, 30:10-14.
4. Escudier B, Eisen T, Stadler W M, et al. Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma. N Engl J Med, 2007, 356: 125-134.
5. Escudier B, Eisen T, Stadler W M, et al. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol, 2009, 27: 3312-3318.
6. Bukowski R, Cella D, Gondek K, et al. Effects of sorafenib on symptoms and quality of life: results from a large randomized placebo-controlled study in renal cancer. Am J Clin Oncol, 2007, 30:220-227.
7. Bellmunt J, Trigo J M, Calvo E, et al. Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOCUC-02-06). Lancet Oncol, 2010, 11:350-357.